Mereo Biopharma Group Plc Quick Ratio (MREO) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Mereo Biopharma Group Plc  (NASDAQ: MREO)

Mereo Biopharma Group Plc's Quick Ratio

MREO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 4.75 below Mereo Biopharma Group Plc average.

Within Major Pharmaceutical Preparations industry 180 other companies have achieved higher Quick Ratio than Mereo Biopharma Group Plc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 510 to 678.

Explain Quick Ratio?
How much Cash & cash equivalents MREO´s has?
What are MREO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MREO/financial-strength
https://api.csimarket.com/api/v1/companies/MREO/fundamentals
https://api.csimarket.com/api/v1/companies/MREO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
MREO Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 37.94 %
Y / Y Cash & cash equivalent Change -46.84 %
Quick Ratio MRQ 4.75
MREO's Total Ranking # 678
Seq. Current Liabilities Change 29.09 %
Seq. Cash & cash equivalent Change -14.45 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 181
Healthcare Sector # 288
Overall Market # 678


Quick Ratio Statistics
High Average Low
19.03 5.14 0.9
(Jun 30 2025)   (Dec 31 2019)




Financial Statements
Mereo Biopharma Group Plc's Current Liabilities $ 5 Millions Visit MREO's Balance sheet
Mereo Biopharma Group Plc's Cash & cash equivalent $ 26 Millions Visit MREO's Balance sheet
Source of MREO's Sales Visit MREO's Sales by Geography


Cumulative Mereo Biopharma Group Plc's Quick Ratio

MREO's Quick Ratio for the trailling 12 Months

MREO Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -25.52 %
Y / Y Cash & cash equivalent TTM Growth -46.17 %
Quick Ratio TTM 6.56
Total Ranking TTM # 3449
Seq. Current Liabilities TTM Growth 8.36 %
Seq. Cash & cash equivalent TTM Growth -15.18 %

Quick ratio ranking by company, industry and sector >> Back to MREO Financial Strength Comparisons >> Go to Compare MREO Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $5.49 millions, cumulative Quick Ratio decreased to 6.56 above the MREO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 417 other companies have achieved higher Quick Ratio than Mereo Biopharma Group Plc. While Quick Ratio overall ranking has improved so far to 3449, from total ranking during the twelve months ending second quarter 2026 at 3483.

Explain Quick Ratio?
How much Cash & cash equivalents MREO´s has?
What are MREO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 418
Healthcare Sector # 851
Within the Market # 3449


trailing twelve months Quick Ratio Statistics
High Average Low
8.27 4.28 0.9
(Dec 31 2025)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Stablecoin Development Corporation  13.01 $ 7.153  Millions$ 0.550  Millions
Uniqure N v   12.78 $ 768.430  Millions$ 60.142  Millions
Rhythm Pharmaceuticals Inc   12.62 $ 320.944  Millions$ 25.438  Millions
Assembly Biosciences Inc   12.61 $ 314.262  Millions$ 24.921  Millions
Dyne Therapeutics Inc   12.53 $ 1,134.386  Millions$ 90.545  Millions
Sensei Biotherapeutics Inc   12.44 $ 174.795  Millions$ 14.049  Millions
Crescent Biopharma Inc   12.32 $ 289.357  Millions$ 23.490  Millions
Spyre Therapeutics Inc   12.24 $ 82.727  Millions$ 6.760  Millions
Edgewise Therapeutics inc   12.10 $ 1,743.893  Millions$ 144.106  Millions
Obsidian Therapeutics, Inc.  11.77 $ 214.905  Millions$ 18.264  Millions
Structure Therapeutics Inc   11.62 $ 1,244.661  Millions$ 107.104  Millions
Immunome Inc   11.27 $ 461.582  Millions$ 40.966  Millions
Korro Bio Inc   11.06 $ 165.015  Millions$ 14.923  Millions
Xenon Pharmaceuticals Inc   10.99 $ 950.798  Millions$ 86.487  Millions
Newamsterdam Pharma Company N v   10.99 $ 628.242  Millions$ 57.154  Millions
Vtv Therapeutics Inc   10.99 $ 77.164  Millions$ 7.024  Millions
Abcellera Biologics Inc   10.85 $ 764.424  Millions$ 70.473  Millions
Cogent Biosciences Inc   10.82 $ 791.134  Millions$ 73.118  Millions
Bicycle Therapeutics Plc  10.57 $ 469.928  Millions$ 44.459  Millions
Lipocine Inc   10.55 $ 21.455  Millions$ 2.034  Millions
Cyclerion Therapeutics Inc   10.32 $ 456.221  Millions$ 44.197  Millions
Lexicon Pharmaceuticals Inc   10.31 $ 183.203  Millions$ 17.773  Millions
Adicet Bio Inc   10.28 $ 174.779  Millions$ 16.996  Millions
An2 Therapeutics Inc   10.26 $ 64.400  Millions$ 6.275  Millions
Pmv Pharmaceuticals Inc   10.15 $ 108.515  Millions$ 10.689  Millions
Nuvectis Pharma inc   9.91 $ 140.707  Millions$ 14.193  Millions
Renovorx Inc   9.76 $ 20.404  Millions$ 2.091  Millions
Aprea Therapeutics Inc   9.52 $ 37.846  Millions$ 3.975  Millions
Rezolute Inc   9.51 $ 89.999  Millions$ 9.463  Millions
Atrium Therapeutics Inc   9.42 $ 232.421  Millions$ 24.663  Millions

Date modified: 2026-11-11T15:46:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.